From: CD40 deficiency mitigates Alzheimer's disease pathology in transgenic mouse models
Genotype Studied area | 4G8-positive plaque (% of area) | Variation (%) when compared to control |
---|---|---|
Tg APP> sw | ||
Frontal cortex | 1.75 ± 0.29 | n/a* |
Occipital cortex | 2.20 ± 0.46 | n/a |
Parietal cortex | 3.22 ± 0.48 | n/a |
Hippocampus | 2.67 ± 0.45 | n/a |
Tg APP sw /CD40 def. | ||
Frontal cortex | 1.06 ± 0.24 | 40% reduction |
Occipital cortex | 1.37 ± 0.33 | 38% reduction |
Parietal cortex | 1.11 ± 0.32 | 66% reduction |
Hippocampus | 0.97 ± 0.30 | 63% reduction |
Tg PSAPP | ||
Frontal cortex | 7.06 ± 0.96 | n/a |
Occipital cortex | 6.77 ± 1.01 | n/a |
Parietal cortex | 6.39 ± 1.03 | n/a |
Hippocampus | 6.99 ± 0.93 | n/a |
Tg PSAPP/CD40 def. | ||
Frontal cortex | 2.34 ± 0.41 | 67% reduction |
Occipital cortex | 1.80 ± 0.19 | 73% reduction |
Parietal cortex | 2.19 ± 0.39 | 66% reduction |
Hippocampus | 2.47 ± 0.43 | 65% reduction |